272 related articles for article (PubMed ID: 23499609)
41. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
42. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.
Nakagawa M; Kim KH; Gillam TM; Moscicki AB
J Virol; 2007 Feb; 81(3):1412-23. PubMed ID: 17108051
[TBL] [Abstract][Full Text] [Related]
43. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
44. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
45. Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes.
Kumar A; Hussain S; Yadav IS; Gissmann L; Natarajan K; Das BC; Bharadwaj M
J Virol Methods; 2015 Jun; 218():51-8. PubMed ID: 25800725
[TBL] [Abstract][Full Text] [Related]
46. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
47. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
[TBL] [Abstract][Full Text] [Related]
48. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
[TBL] [Abstract][Full Text] [Related]
49. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.
Wang X; Moscicki AB; Tsang L; Brockman A; Nakagawa M
Clin Vaccine Immunol; 2008 Jun; 15(6):937-45. PubMed ID: 18448624
[TBL] [Abstract][Full Text] [Related]
50. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches.
Sanami S; Azadegan-Dehkordi F; Rafieian-Kopaei M; Salehi M; Ghasemi-Dehnoo M; Mahooti M; Alizadeh M; Bagheri N
Sci Rep; 2021 Jun; 11(1):12397. PubMed ID: 34117331
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
52. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice.
McCarthy C; Youde SJ; Man S
Int J Cancer; 2006 May; 118(10):2514-21. PubMed ID: 16353149
[TBL] [Abstract][Full Text] [Related]
53. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
[TBL] [Abstract][Full Text] [Related]
54. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
[TBL] [Abstract][Full Text] [Related]
55. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
56. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
57. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer.
Jang S; Kim YT; Chung HW; Lee KR; Lim JB; Lee K
Cancer; 2012 Apr; 118(8):2173-83. PubMed ID: 21918960
[TBL] [Abstract][Full Text] [Related]
59. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
[TBL] [Abstract][Full Text] [Related]
60. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions.
Peng S; Trimble C; Wu L; Pardoll D; Roden R; Hung CF; Wu TC
Clin Cancer Res; 2007 Apr; 13(8):2479-87. PubMed ID: 17438108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
